Differentiation therapy for glioblastoma - too many obstacles?
Helena Carén1, Stephan Beck2, Steven M Pollard3
1Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , 405 30 Gothenburg, Sweden.
Molecular & Cellular Oncology
|June 17, 2016
Abstract
None:
The therapeutic potential of differentiation therapy for glioblastoma will depend on the robustness and stability of the differentiated state. We recently reported several obstacles to bone morphogenetic protein (BMP)-induced differentiation therapy. Improved understanding of the mechanisms that tumor cells use to escape differentiation commitment is urgently needed.


